Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Leukemia-specific delivery of mutant NOTCH1 targeted therapy.

The Journal of experimental medicine - 2 Jan 2018

Roti Giovanni, Qi Jun, Kitara Samuel, Sanchez-Martin Marta, Saur Conway Amy, Varca Anthony C, Su Angela, Wu Lei, Kung Andrew L, Ferrando Adolfo A, Bradner James E, Stegmaier Kimberly

Abstract excerpt

On-target drug delivery remains a challenge in cancer precision medicine; it is difficult to deliver a targeted therapy to cancer cells without incurring toxicity to normal tissues. The SERCA (sarco-endoplasmic reticulum Ca2+ ATPase) inhibitor thapsigargin inhibits mutant NOTCH1 receptors compared with wild type in T cell acute lymphoblastic leukemia (T-ALL), but its administration is predicted to be toxic in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Delivery Systems
Share to Endocytosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Folic Acid

Share to Leukemia

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Receptor, Notch1

Share to Thapsigargin

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29158376
DOI: 10.1084/jem.20151778
PMCID: PMC5748843

Genes

NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Leukemia-specific delivery of mutant NOTCH1 targeted therapy.PMID 29158376Read ↗

Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.Semantic proximity Read ↗

Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Cancer Selective Target Degradation by Folate-Caged PROTACsSemantic proximity Read ↗

Probing the druggability of the Notch1 ankyrin domain using a fragment-based approachSemantic proximity Read ↗

A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.Semantic proximity Read ↗

Targeting NOTCH1 in hematopoietic malignancy.Semantic proximity Read ↗

Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitorsSemantic proximity Read ↗

Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.Semantic proximity Read ↗

AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell SelectivitySemantic proximity Read ↗

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.